Navid Redjal MD, FAANS

Dr. Navid Redjal, director of Neurosurgical Oncology, is a board-certified, Harvard-trained neurosurgeon with extensive research and clinical background in neuro-oncology. He has been involved in significant translational brain cancer research and neuro-oncology clinical trials with research fellowships at the Dana-Farber Cancer Institute and Massachusetts General Hospital.

Dr. Redjal graduated from Harvard Medical School with honors, specifically completing the Harvard-MIT Health Sciences and Technology Society curriculum with a research thesis focusing on targeted therapeutics for brain cancer. After completing medical school, he did his residency at the Massachusetts General Hospital/Harvard neurosurgery program where he also completed a stereotactic proton radiosurgery fellowship. He is board-certified in neurological surgery and a diplomate of the American Board of Neurological Surgery. He is also a Fellow of the American Association of Neurological Surgeons (FAANS).

Following his residency, Dr. Redjal joined the faculty at Harvard Medical School as an instructor in surgery while also serving as an attending neurosurgeon at Massachusetts General Hospital (MGH), a teaching hospital of Harvard Medical School. After his time at MGH, Dr. Redjal joined Kaiser Permanente in Los Angeles as an attending neurosurgeon with a focus in neuro-oncology and worked with neuro-oncologists to advance participation in brain cancer clinical trials.

He specializes in complex brain surgery including awake surgery, language, and motor mapping, minimally invasive neuro-endoscopic surgery utilizing detailed MRI-based neuro-navigation with diffuse tensor imaging and intraoperative ultrasound. He also uses the CyberKnife System in collaboration with radiation oncologists to treat a variety of brain and spine tumors.

Dr. Redjal has conducted significant translational research in targeted local therapy for brain cancer and has been published in a number of medical journals devoted to neurosurgery and cancer research. He has been involved with the Congress of Neurologic Surgeons glioma guidelines committee and has coauthored treatment guidelines for glioblastoma multiforme (GBM) and low-grade gliomas. He currently leads the weekly Neuro-Oncology Multidisciplinary Tumor Board at the Capital Health Cancer Center.